Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.47 |
| ▸ | CES1 | P23141 | 4/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.43 |
| ▸ | HSD17B3 | P37058 | 5/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.42 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.42 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1364678 | 1.00 | CES2 (0.47) | CES2CES1GPR35HSD17B3PLA2G2A | |
| SCHEMBL1365090 | 1.00 | CES2 (0.47) | CES2CES1GPR35HSD17B3PLA2G2A | |
| SCHEMBL10144491 | 0.88 | GPR35 (0.57) | CES2CES1GPR35HSD17B3PLA2G4A | |
| SCHEMBL9948832 | 0.83 | GPR35 (0.49) | GPR35HSD17B3PLA2G4A | |
| SCHEMBL10018136 | 0.83 | GPR35 (0.49) | GPR35HSD17B3PLA2G4A | |
| SCHEMBL14645595 | 0.79 | GSK3B (0.56) | CES2CES1GPR35HSD17B3PLA2G2A | |
| SCHEMBL12374319 | 0.79 | GSK3B (0.56) | CES2CES1GPR35HSD17B3PLA2G2A | |
| SCHEMBL14645639 | 0.79 | GSK3B (0.56) | CES2CES1GPR35HSD17B3PLA2G2A | |
| SCHEMBL1164781 | 0.79 | GSK3B (0.56) | CES2CES1GPR35HSD17B3PLA2G2A | |
| SCHEMBL16507408 | 0.76 | GPR35 (0.36) | CES2CES1GPR35HSD17B3PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571888-B1 | METHODS OF MAKING FUSED THIOPHENES | CORNING INC (US) | 2014-12-31 | — | — | EP | disclosed |
| EP-2571888-A1 | METHODS OF MAKING FUSED THIOPHENES | Corning Incorporated (US) | 2013-03-27 | — | — | EP | disclosed |
| US-8217183-B2 | Methods of making fused thiophenes | CORNING INCORPORATED (US) | 2012-07-10 | — | — | US | disclosed |
| US-20110288306-A1 | METHODS OF MAKING FUSED THIOPHENES | CORNING INCORPORATED | 2011-11-24 | — | — | US | disclosed |
| WO-2011146308-A1 | METHODS OF MAKING FUSED THIOPHENES | CORNING INCORPORATED (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288306-A1 | METHODS OF MAKING FUSED THIOPHENES | DCX, TST, GNPAT | CES2 818/4885CES1 2819/4885GPR35 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.